Dermagnostix has been selected for the prestigious MedTech Innovator (MTI) 2026 Accelerator Cohort, placing the company among the top 4% of medtech startups worldwide.
Chosen from 1,835 applicants, Dermagnostix is one of only 65 companies accepted into the 2026 cohort of MedTech Innovator, the leading U.S.-based accelerator for medical technology companies. The program is designed to de-risk medtech innovation and help high-potential startups accelerate their path to success in the U.S. healthcare market.
Participation in the four-month accelerator provides Dermagnostix with access to leading industry mentors, investors, strategic partners, and a global network of healthcare innovators. The company will also be featured in the newly launched MTI Index 2026, a recognition platform showcasing the most promising companies in medical technology.
This milestone represents an important step in Dermagnostix’s mission to make dermatological diagnostics more accessible, accurate, and impactful for patients and healthcare providers worldwide. It also reflects the dedication of the entire team as well as the continued support of partners, customers, advisors, and investors.
As part of the MedTech Innovator community, Dermagnostix looks forward to collaborating with fellow innovators, gaining valuable insights into the U.S. healthcare ecosystem, and accelerating the development of next-generation solutions for dermatology.
Read the official announcement:
https://medtechinnovator.org/medtech-innovator-unveils-65-startups-in-its-2026-accelerator-cohort-and-launches-the-mti-index-the-definitive-recognition-platform-for-medtech-innovation/
